Elite in Gliosarcoma

Dr. Mark R. Gilbert

Neurology
1515 Holcombe Blvd, 
Houston, TX 
Clinical Trials:Currently Recruiting for 1 Trial
Elite in Gliosarcoma
1515 Holcombe Blvd, 
Houston, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mark Gilbert is a Neurologist in Houston, Texas. Dr. Gilbert is rated as an Elite provider by MediFind in the treatment of Gliosarcoma. His top areas of expertise are Glioma, Gliomatosis Cerebri, Astrocytoma, and Glioblastoma.

His clinical research consists of co-authoring 399 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles and participated in 5 clinical trials in the study of Gliosarcoma.

Specialties
Neurology
Licenses
Psychiatry & Neurology in TX
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D

Locations

1515 Holcombe Blvd, Houston, TX 77030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A First-in-human Phase I Single-agent Dose-escalation, Food Effect and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
A First-in-human Phase I Single-agent Dose-escalation, Food Effect and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Enrollment Status: Recruiting
Publish Date: July 31, 2025
Intervention Type: Drug
Study Drug: ONC206
Study Phase: Phase 1
Evaluation of the Natural History of and Specimen Banking for Patients With Tumors of the Central Nervous System
Evaluation of the Natural History of and Specimen Banking for Patients With Tumors of the Central Nervous System
Enrollment Status: Completed
Publish Date: October 03, 2025
Intervention Type: Other
Phase II Trial Evaluating the Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
Phase II Trial Evaluating the Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drugs: TMZ, Ipilimumab, Nivolumab
Study Phase: Phase 2
A Phase II Trial of Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A)Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
A Phase II Trial of Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A)Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
Enrollment Status: Completed
Publish Date: August 11, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double Blind Phase II Trial of Surgery, Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
A Randomized, Double Blind Phase II Trial of Surgery, Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
Enrollment Status: Terminated
Publish Date: August 08, 2025
Intervention Type: Other, Drug, Biological, Procedure
Study Drugs: Pembrolizumab, Temozolomide, Heat Shock Protein Peptide Complex-96 Vaccine
Study Phase: Phase 2
Phase II Trial of Carboplatin and Bevacizumab for the Treatment of Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma in Adults: A Multi-Center Trial
Phase II Trial of Carboplatin and Bevacizumab for the Treatment of Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma in Adults: A Multi-Center Trial
Enrollment Status: Completed
Publish Date: August 05, 2025
Intervention Type: Drug
Study Drugs: Carboplatin, Bevacizumab
Study Phase: Phase 2
Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients With Recurrent Select Rare CNS Cancers
Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients With Recurrent Select Rare CNS Cancers
Enrollment Status: Completed
Publish Date: June 29, 2025
Intervention Type: Drug
Study Drug: Nivolumab
Study Phase: Phase 2
Phase II Trial of LB100, a Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma
Phase II Trial of LB100, a Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: November 22, 2023
Intervention Type: Drug
Study Drug: LB-100
Study Phase: Phase 2
Phase I Study of Ipilimumab, Nivolumab, and the Combination in Patients With Newly Diagnosed Glioblastoma
Phase I Study of Ipilimumab, Nivolumab, and the Combination in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Completed
Publish Date: January 10, 2023
Intervention Type: Biological, Other, Drug
Study Drugs: Ipilimumab, Nivolumab, Temozolomide
Study Phase: Phase 1
View 8 Less Clinical Trials

399 Total Publications

Characterization of MAIT cells in glioblastoma reveals a potential immunosuppressive role through a MAIT-neutrophil axis.
Characterization of MAIT cells in glioblastoma reveals a potential immunosuppressive role through a MAIT-neutrophil axis.
Journal: Neuro-oncology advances
Published: October 01, 2025
Similar Doctors
Elite in Gliosarcoma
Dr. Shiao-pei Weathers
Neurology
Elite in Gliosarcoma
Dr. Shiao-pei Weathers
Neurology

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
 (0.6 miles away)
713-592-5433
Experience:
16+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Shiao-pei Weathers is a Neurologist in Houston, Texas. Dr. Weathers has been practicing medicine for over 16 years and is rated as an Elite provider by MediFind in the treatment of Gliosarcoma. Her top areas of expertise are Astrocytoma, Glioblastoma, Glioma, and Brain Tumor.

Distinguished in Gliosarcoma
Dr. Vinay K. Puduvalli
Neurology
Distinguished in Gliosarcoma
Dr. Vinay K. Puduvalli
Neurology

MD Anderson

1515 Holcombe Blvd, 
Houston, TX 
 (0.1 miles away)
713-792-2121
Languages Spoken:
English
See accepted insurances

Vinay Puduvalli is a Neurologist in Houston, Texas. Dr. Puduvalli is rated as an Elite provider by MediFind in the treatment of Gliosarcoma. His top areas of expertise are Glioma, Astrocytoma, Glioblastoma, and Gliomatosis Cerebri.

Distinguished in Gliosarcoma
Dr. Marta Penas-Prado
Neurology
Distinguished in Gliosarcoma
Dr. Marta Penas-Prado
Neurology
1515 Holcombe Blvd, 
Houston, TX 
 (0.1 miles away)
713-792-6161
Languages Spoken:
English

Marta Penas-Prado is a Neurologist in Houston, Texas. Dr. Penas-Prado is rated as an Elite provider by MediFind in the treatment of Gliosarcoma. Her top areas of expertise are Astrocytoma, Glioblastoma, Brain Tumor, Glioma, and Tissue Biopsy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gilbert's expertise for a condition
ConditionClose
View All 16 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile